September 28, 2019 10:37 AM EDTUpdated 11:10 AM

Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO

Amber Tong

BARCELONA — Some might consider the dust settled on Merck and Bristol-Myers Squibb’s rivalry over frontline lung cancer, but Bristol-Myers is not giving up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Bristol Myers, Kyowa Kirin disclose layoffs

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Updated: Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

Bank­ing on Op­di­vo/Yer­voy com­bo, Bris­tol-My­ers Squibb teas­es out Check­mate-227 again at ES­MO

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO